Discrepancies in the regulation of plasma adiponectin and TNF-α levels and adipose tissue gene expression in obese African Americans with glucose intolerance: A pilot study using rosiglitazone

Ethnicity and Disease

Volumn 15, Issue 4, 2005, Pages 641-648

  Osei, Kwame ^a   Gaillard, Trudy ^a   Cook, Charles ^a   Kaplow, June ^b   Bullock, Matthew ^b   Schuster, Dara ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Adiponectin; African Americans; Insulin resistance; Insulin Secretion; mRNA; Rosiglitazone; Tumor necrosis factor alpha

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; C PEPTIDE; CYTOKINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MESSENGER RNA; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG TOLERABILITY; ETHNOLOGY; FEMALE; GLUCOSE HOMEOSTASIS; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PILOT STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT;

ADIPONECTIN; ADIPOSE TISSUE; ADULT; AFRICAN AMERICANS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY; PILOT PROJECTS; RNA, MESSENGER; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27844457075     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Fernandez-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia. 1999;42:1367-1374.
2. Krakoff J, Funahaser T, Stenhouwer CDA, et al. Inflammatory markers, adiponectin, and the risk of type 2 diabetes in the Pima Indians. Diabetes Care. 2003;26:1745-1751.
3. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-1935.
4. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazoldinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51: 2968-2974.
5. Phillips SA, Ciaradi TP, Kong APS, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003;52:667-674.
6. Peline F, Smith U, Funahashi T, et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes. 2003;52:1182-1186.
7. Lihn AS, Ostergard T, Nyholm B, Pederson SB, Richelsen R, Schmitz O. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2003;284: 443-452.
8. Lindsay RS, Funahasha T, Hansen RI, et al. Adiponectin protects against development of type 2 diabetes in Pima Indian population. Lancet. 2002;360:57-58.
9. Cnop M, Havel PJ, Ultzchneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity, and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 2003;46:459-469.
10. Osei K, Gaillard T, Kaplow J, Bullock M, Schuster D. Effects of rosiglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism. 2004;53(12):1552-1557.
11. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp 30 enhances hepatic insulin action. Nat Med. 2001;7:947-953.
12. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thomb Vasc Biol. 2003;23:85-89.
13. Ouchi N, Kumada M, Kihara S, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473-2476.
14. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF - a by human muscle. Relationship to insulin resistance. J Clin Invest. 1996;97:1111-1116.
15. Straczkowski MA, Kowalska I, Stepien A, Dziena- Straczkowska S, Straczkowska M, Kinalska I. Plasma-soluble tumor necrosis factor alpha-receptors level in lean, nondiabetic offspring of type 2 diabetic subjects. Diabetes Care. 2002;25:1824-1828.
16. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor alpha: direct role in obesity linked insulin resistance. Science. 1993;259:87-91.
17. Brunn JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue derived adipcytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285:E527-E533,
18. Kern PA, Saghisadeh M, Ong JM, Bosch RJ, Deem R, Sims RB. The expression of tumor necrosis in human adipose tissue; regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995;95: 2111-2119.
19. Cheung A, Ree D, et al. An in vivo model for elucidation of the mechanism of tumor necrosis factor-α (TNF-α)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-α. Endocrinology. 1998;139:4928-4935.
20. Moller D. Potential role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000;11: 212-217.
21. Naitoh T, Kitahara M, Tsuruzoe N. The effect of activation of peroxisome proliferator-activated receptor gamma (PPARγ) on human monocyte function: PPARγ ligands do not inhibit tumor necrosis factor-α release in human monocytic cell line THP-1. Cell Biol Toxicol. 2000;16:131-135.
22. Fukuzawa M, Satoh J, Qiang X, et al. Inhibition of tumor necrosis factor-α with anti-diabetic agents. Diab Res Clin Pract. 1999;43:147-154.
23. Moore GBT, Chapman H, Holder JC, et al. Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophysical Res Communications. 2001;286:735-741.
24. Mathews DR, Hosker JP, Rudenski AS, Taylor BA, Treacher DF, Turner RC. Homeostasis model assessment insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
25. Reynolds LR, Konz EC, Frederich RG, Anderson JW. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-term, type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:270-275.
26. Buchanan TA. Pancreatic beta cell defects in gestational diabetes. Implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:989-993.
27. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women. Diabetes. 2002;51: 2796-2803.